Abstract Introduction:Cannabis sativa produces hundreds of bioactive compounds, including cannabinoids and terpenoids. It has been proposed that cannabinoids act in…
Abstract Background: In 2016, the Australian federal government passed legislation enabling a range of cannabis-based products to be prescribed to…
Abstract Objective: Cannabidiol (CBD) has been approved by the US Food and Drug Administration (FDA) to treat intractable childhood epilepsies,…
Abstract Introduction: Compounds present in Cannabis sativa such as phytocannabinoids and terpenoids may act in concert to elicit therapeutic effects.…
Abstract Cannabidiol (CBD) is currently being investigated as a novel therapeutic for the treatment of CNS disorders like schizophrenia and…
Abstract Recent analysis of the cannabinoid content of cannabis plants suggests a shift towards use of high potency plant material…
Abstract Neuregulin 1 (NRG1) is linked to an increased risk of developing schizophrenia and cannabis dependence. Mice that are hypomorphic…
Abstract The link between cannabis and psychosis has been debated although there is substantial epidemiological evidence showing that cannabis increases…
Abstract The ABC transporters P-glycoprotein (P-gp, Abcb1) and breast cancer resistance protein (Bcrp, Abcg2) regulate the CNS disposition of many…
Abstract The cannabis constituent cannabidiol (CBD) possesses anxiolytic and antipsychotic properties. We have previously shown that transmembrane domain neuregulin 1…